CLOVIS ONCOLOGY INC (NASDAQ:CLVS)

Jefferies Has Top Health Care Stocks to Buy as Sector Explodes

During 2015 and last year as the brutal presidential campaign played out, the health care sector, and especially the drugmakers, became one of the favorite whipping boys for the candidates, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Biogen, Equifax, Foot Locker, GE, NVIDIA, Rio Tinto, Roku and More

Stocks have hit new highs and the Dow Jones Industrial Average went well above 23,000 by 300 points last week. Stocks were also indicated to open higher on Monday. The ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AK Steel, Altice USA, Biogen, Caterpillar, Gilead, Oracle and Many More

Stocks have recently hit all-time highs again, but the stock indexes seem to have gone sideways in recent days and they were looking for direction on a slow news Friday. ...
Read Full Story »

Clovis Looks to Cash in on Secondary Offering

Shares of Clovis Oncology Inc. (NASDAQ: CLVS) saw a handy gain in Wednesday’s session after the company priced its secondary offering. This offering comes on the heels of a massive ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amex, ADP, Goodyear, McDonald’s, National Oilwell Varco, NVIDIA, Vivint Solar and Many More

Stocks hit all-time highs yet again on Monday and the Dow has now gone above the 24/7 Wall St. 2017 price target issued at the start of this year. The ...
Read Full Story »

Clovis Oncology Surges on Clutch Late-Stage Ovarian Cancer Trial

Clovis Oncology Inc. (NASDAQ: CLVS) saw its shares make a massive gain early on Monday after the company announced top-line data from its confirmatory Phase 3 Ariel3 trial of rucaparib ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AMD, ConocoPhillips, Etsy, Marathon Oil, Square, Disney, Windstream and More

Stocks were indicated to open lower on Wednesday, but this is after many days of gains and with equity indexes close to their highs. The bull market is now more ...
Read Full Story »
thumbs up

Merrill Lynch Raises Price Targets on 3 Red-Hot Tech and Biotech Stocks

While there is no question the market seems very tired, some very compelling stocks to buy that have a great story still offer investors decent upside potential. At 24/7 Wall ...
Read Full Story »
approve disapprove

Top Analyst Upgrades and Downgrades: Alcoa, Altria, Ford, GoPro, NVIDIA, International Paper, Transocean and Many More

Stocks have seen big swings in a mixed week. There was a dovish Fed meeting that gave no directional bias on rates, and now we have a much stronger than ...
Read Full Story »
analysis

Top Analyst Upgrades and Downgrades: Hasbro, Johnson & Johnson, Mattel, MetLife, United Rentals, UTC, Williams and More

Stocks rallied on Tuesday and then really got a bump on Wednesday, and the Dow Jones Industrial Average finally cracked the 20,000 level. There remains a path to Dow 21,422 ...
Read Full Story »
Prescription drugs

Tuesday’s Biggest Biotech and Pharma Moves

To kick off the New Year, a few biotech companies made massive runs on this first day of trading in 2017. The health care sector was in trouble over the ...
Read Full Story »
thumbs up and down

Key Analyst Upgrades and Downgrades for Tuesday: Alcoa, Arch Coal, Baidu, Ciena, JD.com, Vale and Many More

Stocks were indicated higher on Tuesday, with the Dow Jones Industrial Average still 50 points shy of DJIA 20,000 right after the opening bell. Stocks are challenging last week's all-time ...
Read Full Story »
Female patient on gurney

Clovis Wins Key FDA Approval on Ovarian Cancer Treatment

Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares hit a new 52-week high after the company reported a key U.S. Food and Drug Administration (FDA) approval. Essentially, the FDA ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Netflix, Nike, Pandora, SunPower, United Continental and More

Stocks closed higher on Monday and were indicated even higher again on Tuesday. The ongoing theme is that investors have not tired of what is close to an eight-year bull ...
Read Full Story »
thumbs up

How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again

Clovis Oncology Inc. (NASDAQ: CLVS) posted a massive gain of 27% to $23.03 on Tuesday, on the heels of news that the Food and Drug Administration (FDA) had granted it ...
Read Full Story »